KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Assets (2016 - 2025)

Pacira BioSciences has reported Non-Current Assets over the past 16 years, most recently at $716.9 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $716.9 million for Q4 2025, down 11.31% from a year ago — trailing twelve months through Dec 2025 was $3.1 billion (down 16.91% YoY), and the annual figure for FY2025 was $716.9 million, down 11.31%.
  • Non-Current Assets for Q4 2025 was $716.9 million at Pacira BioSciences, down from $734.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PCRX hit a ceiling of $1.2 billion in Q1 2022 and a floor of $533.3 million in Q2 2021.
  • Median Non-Current Assets over the past 5 years was $1.0 billion (2024), compared with a mean of $941.8 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 126.49% in 2022 and later decreased 24.05% in 2024.
  • Pacira BioSciences' Non-Current Assets stood at $1.2 billion in 2021, then fell by 2.19% to $1.2 billion in 2022, then dropped by 10.02% to $1.1 billion in 2023, then fell by 24.05% to $808.4 million in 2024, then dropped by 11.31% to $716.9 million in 2025.
  • The last three reported values for Non-Current Assets were $716.9 million (Q4 2025), $734.8 million (Q3 2025), and $791.6 million (Q2 2025) per Business Quant data.